United States
Print page content Print
Increase text size Decrease text size
Text Size

In this section

MOA

PALLADIA is the only canine cancer therapy with antiangiogenic and antiproliferative effects

  • PALLADIA inhibits VEGFR-2 on endothelial cells and PDGFR-ß on pericytes for an antiangiogenic effect1,2
  • PALLADIA inhibits KIT on tumor cells for an antiproliferative effect1
  • The simultaneous inhibition of these RTKs blocks multiple processes necessary for tumor growth10,11,12,13

Click here to watch the MOA video

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040

REFERENCES:

1. Package Insert
2. London CA et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9:2755-68.
10. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111:1287-1295.
11. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 2006;5:1280-1289
12. Liao AT, Chien MB, Shenoy N, et al. Proof of target for SU11654: inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002;100:585-593.
13. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734.